IFRX
InflaRx N.V.NASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$69.92M
P/E Ratio
—
EPS
$-0.78
Beta
1.51
52W High
$1.94
52W Low
$0.71
50-Day MA
$0.91
200-Day MA
$1.07
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About InflaRx N.V.
InflaRx NV, a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company is headquartered in Jena, Germany.
Fundamentals
| Revenue (TTM) | 29,330 |
| Gross Profit (TTM) | $-7.24M |
| EBITDA | $-48.20M |
| Operating Margin | 37898.00% |
| Return on Equity | -88.60% |
| Return on Assets | -46.00% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $0.67 |
| Price-to-Book | 1.37 |
| Price-to-Sales (TTM) | 2383.88 |
| EV/Revenue | 387.01 |
| EV/EBITDA | 0.50 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -80.80% |
| Shares Outstanding | $72.29M |
| Float | $60.02M |
| % Insiders | 5.98% |
| % Institutions | 27.25% |
Analyst Ratings
Consensus ($8.99 target)
1
Strong Buy5
Buy2
HoldData last updated: 4/8/2026